Recommended Dose: Escalating dosing schedule with a 21-day cycle for up to 12 cycles: 2.5mg on Cycle 1 Day 8, 10mg on Cycle 1 Day 15, then 30mg fixed dose on Day 1 of Cycle 2-12. Pre-treatment with obinutuzumab is required 7 days before the first dose.

Time: 21 days per treatment cycle. Infuse on Day 8 & Day 15 of Cycle 1, then Day 1 of each subsequent cycle. Each infusion lasts about 4 hours.

Instructions for use: For intravenous infusion only with a 0.2μm sterile in-line filter. Administer under supervision in qualified oncology centers. Pre-medication and adverse reaction monitoring are required. Do not administer as bolus injection, rapid infusion, or vigorously shake the vial.

Interaction: It may suppress CYP enzyme activity via cytokine release, raising exposure of CYP-metabolized drugs. Monitor toxicity or drug levels of CYP substrates during co-administration. Avoid unregulated combination with immunosuppressive agents that raise infection risks.

Side effects: Common adverse reactions include cytokine release syndrome, tumor flare reaction, diarrhea, nausea, constipation, fatigue and neutropenia. Most adverse events are manageable with dose adjustment and symptomatic treatment.